
Enable job alerts via email!
Generate a tailored resume in minutes
Land an interview and earn more. Learn more
A leading health security agency in Cambridge is seeking a researcher for the Antimicrobial Development team. The role involves screening novel therapies against priority pathogens, particularly focusing on AMR. Essential qualifications include experience with ACDP2 pathogens and high throughput screening. The successful candidate will work independently and lead research efforts. Desirable skills include programming with R and laboratory robotics experience, along with supervisory experience.
The United Kingdom Health Security Agency (UKHSA) is a system leader for health security; taking action internationally to strengthen global health security, providing trusted advice to government and the public and reducing inequalities in the way different communities experience and are impacted by infectious disease, environmental hazards, and other threats to health.
UKHSA’s remit, as an agency with a global-to-local reach, is to protect the health of the nation from infectious diseases and other external threats to health. As the nation’s expert national health security agency UKHSA will:
The Countermeasures Development and Evaluation Centre is based at Porton and has approximately 250 staff, performing a range of research activities, including high containment level work. The department’s work covers a broad range of projects involving vaccine and therapeutic, discovery, evaluation, development, and research.
The Antimicrobial Development, Discovery and Diagnostics (AD3) team sits in the Countermeasures Development, Evaluation and Preparedness Division in the Public Health Microbiology Directorate within the Chief Scientific Officer Group. Its work focuses on the discovery, development and evaluation of antimicrobial therapies directed at UKHSA priority pathogens, with a particular focus on AMR/emerging pathogens. The post holder will be involved in screening novel therapies, including non-traditional therapies such as bacteriophage and antimicrobial peptides, for antimicrobial activity against ACDP2 bacteria and fungi.